



Molecular Structure, Electronic and Topology of Pyranopyrazole Derivatives and their Molecular Docking with DNA and Protein to evaluate Anticancer Potential

Article Type: Research Article	Authors: Abdul Ghafoor ^{1,2*} , Muhammad Amir Abass ³ , Javed Ali ¹ , Manahal Abbas ¹ , Sadia Shabbir ¹ , Rakia Ali ¹ , Amin Abid ¹ , Nouman Ahmad ¹
Article publication history: Article Received on: 29-Jun-25 Article Accepted on: 27-Aug-25 Article Published on: 30-Sep-25	Affiliation:
Article review details:	¹ <i>Department of Chemistry, University of Sahiwal, Sahiwal, Pakistan</i>
Reviewed by: Dr. D. Kalyani	² <i>Department of Chemistry, Riphah International University, Sahiwal Pakistan</i>
Second Review by: Dr. Naresh Chanchal	³ <i>Department of Chemistry, Bahauddin Zakariya University Multan, Pakistan</i>
Final Approval by: Dr. Idris Ansari	Corresponding Email: agorg_ch@yahoo.com

Abstract

The synthesized derivatives of pyranopyrazole (**AG.1-14**) are presented in this work as anti-breast cancer medications, and their geometries are determined by functionalized density functional theory (DFT) calculations. Fluctuations in global reactive descriptor energy and in electrostatic potential were measured by frontier molecular orbital (FMOs) and molecular electrostatic potential (MEP) studies. These derivatives may be used as lead compounds in the development of medications that combat breast cancer. To find out which target molecules can connect to the DNA and 3ert protein in blood cells, molecular docking research has also been done. Molecular docking is used to assess their potential to treat cancer, especially breast cancer. Finding the quantum chemical features of the pyranopyrazole (**AG.1-14**) compound's derivatives that exhibit a significant function in pharmaceutical sector is the goal of current study.

Keywords: Pyranopyrazole, DFT, FMO Analysis, Topology, Molecular Docking

Introduction

Currently, one of the primary causes of death globally is infectious diseases. As living standards have increased, consequently has the incidence of cancer, which is now the biggest hazard to human health [1], [2]. At the moment, one of the biggest challenges facing scientists is creating novel drugs to treat the great majority of illnesses.[3]. To manage these disorders heterocycles are crucial constituents of numerous natural materials and hold great significance in the field of organic chemistry[4],[5],[6]. Although traditional treatments like radiation and surgery are incredibly effective in treating some cancers, they still have limited success in curing aggressive tumours. Chemotherapy, a cornerstone of multidisciplinary cancer care, is substantially compromised by the significant toxicities of many anticancer drugs, which negatively impacts patients' quality of life[7]. Thus, it is now essential for medicinal chemists to design anticancer medications with excellent selectivity and minimal toxicity. Because of the structural stiffness that their diverse spatial conformations bestow, several heterocycles have distinctive anticancer actions that are mediated by specialised binding to cancer targets[8]. Nitrogen-containing heterocyclic compounds are considered the most prevalent class of chemical substances, encompassing biologically active complexes and molecules widely utilized in medicinal chemistry.[9],[10]. Pyranopyrazole moieties are a significant class of heterocyclic compounds that includes both natural and manufactured molecules. They are composed of oxygen and nitrogen ring fused heterocycles, and among them, they have demonstrated exceptional biochemical behaviors and activities, providing a flexible framework for the development of novel drugs [11]. They have been integrated as fundamental components of diverse pharmacologically effective scaffolds [12],[13],[14]. Pyranopyrazoles' well-known antibacterial properties[15], antimicrobial, anticancer[16], anti-inflammatory, analgesic[17], antidiabetic and cholinesterase-inhibiting as well as for how well they work to treat Alzheimer's[18],[19], [20]. Additionally, they function as possible inhibitors of human Chk1 kinase[21]. As a result, a number of economical synthetic procedures that employ less expensive substrates, reusable catalysts, and environmentally acceptable solvents to synthesize pyranopyrazole derivatives have been produced. Asif et al. revealed a few new spirooxindole-pyranopyrazole compounds and assessed the National Cancer Institute's (NCI), 60 cell lines for human cancer were tested for in vitro anticancer activity [22]. The compounds caused a 43.19% reduction in proliferation in the lung cancer cell line HOP92 and a maximum development suppression of 82% in the colon cancer cell line KM12 at 10 μ M [22]. Saleh et al. manufactured new pyrazolopyranopyrimidine compounds used an MTT assay to evaluate their anticancer effects against MCF7 breast cancer cells [23]. The most cytotoxic compounds were those with barbituric acid and hydroxyl groups, particularly those with the hydroxyl group at the benzene ring's 4-position. The compounds showed the greatest inhibition capacity against MCF7, with an IC50 value of 145 μ M/mL.

In addition to synthesis and characterization, understanding a compound is essential because of the connection between its structure and function. Various biological targets and pyranopyrazole compounds are investigated for possible interactions using molecular docking experiments. Docking analysis was employed to deeper comprehend ways of inhibition and manner of connections. [24]. It is employed to forecast how small compounds will interact to a protein target's binding site [25]. This approach is particularly effective in determining the three-

RESULTS AND DISCUSSION







Figure 1: Structural formulae of pyrano[2, 3-c]pyrazole derivatives (AG.1-14)

Quantum computational details

Gaussian 09 and DFT were used to optimize the compound's molecular geometry completely at B3LYP/6-311++G(d,p) level basis set. Additionally, ESP surface map, electrical characteristics, and global reactive descriptor investigations were all analyzed using the Multiwfn program. The PyMol application was used to develop the lower energy structure of the pyranopyrazole derivatives and save it as a PDB formatted document prior to molecular docking. Autodock tools conducted the docking procedure after obtaining the selected protein in PDB format from the website tool.

Molecular geometry

The optimal structure of the compound was found in the present work using 6-311++G(d,p) basis set and DFT at B3LYP level. This ideal configuration has been discovered when smallest worldwide minimum energy is -2.6882 kcal/mol and dipole moment is 1.5384 Debye is depicted in Fig. 1. We identified two structurally comparable compounds whose properties in order to compare the bond length as well as bond angle theoretical values as a function of the compounds. Since heavier molecule attached at positions C11 and C12, which are thought to be weakest sites in this molecule, longest distance between bonds, 1.187 Å, calculated for CN-C17 & NH₂-C18 based on optimized result. These results are in excellent accordance with those reported in the literature (1.787 & 1.807 Å). The range of CN-C CN-C bonds is normally 1.77-1.78 Å, however due of the difference in atoms' electronegativity, It is far more extensive and the computed nearby C-C bonds (C10-C17 & C11-C18) are correspondingly shorter (1.531 Å). O3 and C19, This was dualistic in their dedication to them., were determined to have the most powerful bonds in molecule. As a result, the shortest distance for O3-H37 and O4-C19 are 0.97 and 1.207 Å, respectively, and these values are also in line with published values (1.006 & 1.228 Å). Furthermore , N5-C7, N5-C10, N5-C11, N6-C12, N6-H35 and N6-H36 are the significant calculated nitrogen attached bonds, with distances of 1.399, 1.455, 1.455, 1.463, 1.016 and 1.015 Å, respectively; the C-C bonds in the benzene ring are C9-C15, C9-C16, C13-C15, C14-C16, C7-C13 and C7-C14, with respective values of 1.398, 1.397, 1.39, 1.391, 1.41 and 1.409 Å. Bond angles of all derivatives are shown insupplimentary file (**Table 1**). There is no need for a lengthy description because the majority of which the bond angle variables are fairly similar to those that are commonly observed in structures with similar compound structures. The geometry optimisation of all derivatives is depicted in Figure 2.

**AG.1****AG.2****AG.3****AG.4****AG.5****AG.6****AG.7****AG.8**




Figure 2 Geometry optimisation of molecules (AG.1-14)


FMOs analysis

The energy values of orbitals that are filled and empty (HOMO & LUMO) can be utilized to comprehend the pharmacokinetics as well as stability of pyranazole molecule. High chemical excitability and a short FMO band gap characterize soft substances. To investigate derivatives of pyranazoles In this case, the effect of the solution was better explored. The spectral gap (ΔE) can

be understood in Table 1. The band gap energies for various pyranazole derivatives are 3.7481, 3.79441, 4.9463, and 4.9420 eV. Narrow band gap indicating that the molecules are significantly more reactive. The lowest gaps are recorded for AG.14 and AG.13 at 3.7477 eV and 3.7945 eV, respectively, due to a noteworthy rise in E_{HOMO} and decreasing E_{LUMO} . For AG14 complex, the E_{HOMO} , E_{LUMO} , and $E_{\text{H-L}}$ values are -6.6351, -2.8877, and 3.7477 eV, while for AG13 complex, they are -6.6626, -2.8680, and 3.7945 eV. The largest gap is found for AG.1 complex. In the case of AG.2 complex, the E_{HOMO} , E_{LUMO} , and $E_{\text{H-L}}$ values are -6.3328, -1.2517, and 5.0810 eV. Minimal HOMO-LUMO gaps imply that the reactivity of these compounds might be increased.

Table 1: The E_{HOMO} , E_{LUMO} and $E_{\text{H-L}}$ all complexes in eV

Complexes	E_{H} (eV)	E_{L} (eV)	$E_{\text{L}} - E_{\text{H}}$ (eV)
AG1	-6.3309	-1.8630	5.1445
AG2	-6.3328	-1.2517	5.0810
AG3	-6.4413	-1.3605	5.0800
AG4	-6.5222	-1.4628	5.0594
AG5	-6.4343	-1.3877	5.0466
AG6	-6.2982	-1.2517	5.0464
AG7	-6.2383	-1.2130	5.0246
AG8	-6.1815	-1.1934	4.9570
AG9	-6.1622	-1.2100	4.9521
AG10	-6.0715	-1.1934	4.8780
AG11	-6.0800	-1.2215	4.8584
AG12	-6.0024	-1.2117	4.7906
AG13	-6.6626	-2.8680	3.7945
AG14	-6.6351	-2.8877	3.7477






Figure 3. The E_{HOMO} figures of all derivatives of Pyranopyrazole Scaffolds as active anti-breast cancer drug









Figure 4.The E_{LUMO} figures of all derivatives of Pyranopyrazole Scaffolds as active anti-breast cancer drug


MESP analysis and Reactivity Trends

The molecular electrostatic potential (MEP) surface analysis of the pyranopyrazole derivatives (**Fig. 5**) reveals distinct reactivity regions, correlating with the atomic charge distributions observed in AG1–AG14. The MEP minima (negative values, red regions) identify nucleophilic attack sites, with the most pronounced electrostatic potentials localized at NH₂ (−32.85 to −36.58 kcal/mol) and O4 (−19.12 to −35.62 kcal/mol), consistent with the high negative charges on nitrogen (N3/N25: −0.32 to −0.68 |e|) and oxygen (O17: ∼−0.47 |e|) atoms in the atomic charge analysis. Conversely, MEP maxima (positive values, blue regions) highlight electrophilic attack sites, notably at CH₂ (C8-H20-H21) (+48.64 to +52.95 kcal/mol), aligning with the moderate positive charges on C8 (∼0.44–0.53 |e|) in AG1–AG10. The exceptional polarization in AG11–AG14 (e.g., C11: −1.58 to −1.63 |e|) further rationalizes the intensified MEP minima near π -withdrawing groups, while AG5's anomalous C7 charge (+0.82 |e|) underscores the impact of heterocyclic distortion on electrostatic potential. These results confirm that NH₂ and O₂ serve as primary nucleophilic centers, whereas CH₂ moieties are key electrophilic targets, with charge delocalization in AG11–AG14 enhancing reactivity contrasts.


**AG.1****AG.2****AG.3****AG.4**




AG.5




AG.6




AG.7




AG.8




AG.9



AG.10



AG.11



AG.12




Figure 5: The MEP diagram of all derivatives of Pyranopyrazole Scaffolds as active ssanti-breast cancer drug

Electrostatic potential map

The Electrostatic Potential (ESP) is associated with electron density and offers valuable insights into the molecule's reactivity, particularly toward electrophilic attacks. In Figure 5, ESP values are illustrated using a color gradient: red indicates the most electronegative regions, while blue signifies the most electropositive areas. The increasing order of potential follows the sequence: red < orange < yellow < green < blue. The ESP surface map was generated using the B3LYP/6-31++G basis set, based on the total electron density grid. The oxygen atom in the carbonyl group emerges as the most electrophilic site due to the significant electronegativity difference. The deep blue region highlights the most positively charged area, representing a favorable site for nucleophilic attack. These positive regions are primarily localized around the hydrogen atoms.

Red < orange < yellow < green < blue

Global reactivity descriptors

To evaluate the reactivity of these clusters, global reactivity descriptors including chemical hardness, chemical potential, and softness were calculated. Resistance to changes in the electronic distribution within clusters is used to quantify chemical hardness. Based on the information, the hardness value (2.55 eV) of the AG2, AG3, AG4, and AG5 cluster is the highest, while the AG13 & AG14 cluster has the lowest value. Table 3 demonstrates a positive link between decreasing values and larger sizes, indicating softness and reactivity. Comparably, the chemical softness (S) values rise from AG14 to AG01 and peak at 1.275 eV. Additionally, the chemical potential values are computed and provided in the table. The tendency of electrons in clusters to escape is indicated by greater chemical potential (μ) values. The stability of these clusters is indicated by the molecules that obtained significant values (negative). These numbers also imply that the clusters have a reasonable level of electrical stability and do not spontaneously break down into atoms. As stated by using Koopman's theorem, negative energy of a LUMO is roughly equal to EA, while the negative energy of a HOMO is roughly identical to

IP. The computation of other important factors like η , S , ω , and μ is done using the E_{HOMO} and E_{LUMO} . The following formulas to get the vertical electron affinity (EA) and vertical ionization potential (IP):

$$\text{IP} = -E_{\text{HOMO}}(\text{eV})$$

$$\text{EA} = -E_{\text{LUMO}}(\text{eV})$$

Similarly, electronegativity (χ) chemical potential (μ), chemical hardness (η) electrophilicity index (ω) and chemical softness (s) are computed by equations

$$\mu = -(\text{IP} + \text{EA})/2$$

$$\eta = \text{IP} - \text{EA}/2$$

$$S = 1/2\eta$$

$$\Omega = \mu^2/2\eta$$

Table 3: The Frontier Molecular Orbital (FMO) analysis involved the calculation of several parameters, including the highest occupied molecular orbital energy (E_{HOMO}), lowest unoccupied molecular orbital energy (E_{LUMO}), energy gap (ΔE_{g}), ionization potential (IP), electron affinity (Ea), chemical hardness (η), chemical softness (S), electronegativity (χ), chemical potential (μ), and electrophilicity index (Ω). All values were expressed in electron volts (eV).

Compounds	E_{HOMO} (eV)	E_{LUMO} (eV)	ΔE (eV)	IP (eV)	EA (eV)	χ	μ	η	S	Ω
AG.1	-6.33	-1.86	5.14	6.3	1.8	4.05	-4.05	2.25	1.125	-3.64
AG.2	-6.32	-1.25	5.08	6.3	1.2	3.75	-3.75	2.55	1.275	
AG.3	-6.44	-1.36	5.08	6.4	1.3	3.85	-3.85	2.55	1.275	
AG.4	-6.52	-1.46	5.05	6.5	1.4	3.95	-3.95	2.55	1.275	
AG.5	-6.43	-1.38	5.04	6.4	1.3	3.85	-3.85	2.55	1.275	
AG.6	-6.29	-1.25	5.04	6.2	1.2	3.70	-3.70	2.50	1.250	
AG.7	-6.23	-1.21	5.02	6.2	1.2	3.70	-3.70	2.50	1.250	
AG.8	-6.18	-1.19	4.95	6.1	1.1	3.60	-3.60	2.50	1.250	
AG.9	-6.16	-1.21	4.95	6.1	1.2	3.65	-3.65	2.45	1.225	
AG.10	-6.07	-1.19	4.87	6.0	1.1	3.55	-3.55	2.45	1.225	
AG.11	-6.08	-1.22	4.85	6.0	1.2	3.60	-3.60	2.40	1.200	
AG.12	-6.00	-1.21	4.79	6.0	1.2	3.6	-3.6	2.40	1.200	
AG.13	-6.66	-2.86	3.79	6.6	2.9	4.75	-4.75	1.85	0.925	

AG.14	-6.63	-2.88	3.74	6.6	2.9	4.75	-4.75	1.85	0.925	
--------------	-------	-------	------	-----	-----	------	-------	------	-------	--

Molecular Docking

A computer method called molecular docking estimates how well ligands will bind to proteins that serve as receptors. In recent years, molecular docking has become a vital tool in the in-silico drug design process. It involves predicting, at the atomic level, how a small molecule will interact with a target protein. For molecular docking strategies, a number of free and commercial computational tools and algorithms are obtainable [38].

By applying the AutoDock Vina program, the docking evaluation of pyranopyrazole derivatives (**AG.1-14**) was done. The protein data bank (PDB ID: IBNA) provided the crystal structures for each of proteins and DNA. By eradicating water molecules and introducing polar hydrogens, the DNA and proteins were altered for docking. DNA's Kollman charges were computed. The gas phase pyranopyrazole derivatives (**AG.1-14**) were created for docking process by the optimization process. The Geistenger method was also used to figure out the molecule's partial charges. The 40Å×40Å×40Å grid size was used to define the DNA and protein active sites. Through hydrogen bonding interactions, the pyranopyrazole derivatives (**AG.1-14**) attach to the active sites of proteins and DNA.

With DNA and the 3ert protein, each derivative of pyranopyrazole (**AG.1-14**) exhibits nine distinct postures with varying binding affinity values. The findings showed that the derivatives of AG.7 and AG.14 had the maximum binding affinity (ΔG) when docking with DNA, at -8.2 and -8.0 kcal/mol. However, in case of protein, AG.7 derivatives exhibit the highest binding affinity. AG.7's binding affinity (ΔG) was measured at -8.6 kcal/mol.

Different visualizing docking pictures are given which shows binding or interactions of ligands AG.1-14 with 3ert and DNA. The molecular docking with 3ert and DNA is represented in Fig 4.10(a-d) and Fig 4.11(a-d) respectively.




Figure 6: Molecular Docking of AG.1 with DNA.




Figure 7: Molecular Docking of AG.2 and AG.3 with DNA




Figure 8: Molecular Docking of AG.4 and AG.5 with DNA.




Figure 9: Molecular Docking of AG.6 and AG.7 with DNA.




Figure 10: Molecular Docking of AG.8 and AG.9 with DNA.






Figure 12: Molecular Docking of AG.12 and AG.13 with DNA.**Figure 13:** Molecular Docking of AG.14 with DNA.

In all abovefigures, (A) Docking of pyranopyrazole derivatives (**AG.1-14**) with DNA. (B) The detailed interaction of optimized structure of pyranopyrazole derivatives (**AG.1-14**) with DNA, the dotted lines show the interaction of pyranopyrazole derivatives (**AG.1-14**). (C) It is represented the ligand pose with DNA in solid phase. These dotted lines show hydrogen bonding of ligand compounds with DNA.




Figure 4.10d: Molecular Docking of AG.7 with 3ert.

CONCLUSION

Bond lengths and bond angles from geometric optimization using the B3LYP/6-31++G(d,p) basis sets were found to be in reasonable accordance with the published literature. B3LYP/6-31++G(d,p) shift was determined to be more consistent with the published results of experiments. The structure's stability and H-bonding were demonstrated by the higher disturbance energy obtained from NBO analysis. A smaller HOMO-LUMO energy gap provided the proper orbital transition. AG.1-14 displayed a greater charge transfer. The ESP contour map demonstrated a robust charge transfer within the molecules, while global reactivity descriptor provided information on the molecule's hardness and softness. Because of the arrangement of Mulliken charges, the title compound's oxygen has a negative charge, making it an ideal site for electrophilic attack.

Molecular docking of these named compounds was done using 3ert protein and DNA at the final phase of this research. Each of the nine different pyranopyrazole derivatives shows different binding affinities with DNA and 3ert protein. The outcomes demonstrated the following order of binding affinities for derivatives designated as AG.1-14.

The increasing order of AG.1-AG.14 compounds in case of DNA as;

AG.7< AG.14< AG.5=AG.8= AG.10< AG.1= AG.9=AG.12= AG.13< AG.2= AG.3=< AG.4< AG.6<AG.11

The increasing order of AG.1-AG.14 compounds in case of protein as;

AG.7< AG.5< AG.9< AG.3= AG.8< AG.1=AG.10< AG.2AG.4= AG.6=AG.13< AG.14< AG.11=AG.12

ACKNOWLEDGEMENT

We thank Dr. Amin Abid from Department of Chemistry, University of Sahiwal, for helpful suggestions and complete assistance with preparing figures and manuscript outline.

Author Contributions

Abdul Ghafoor wrote the main manuscript Draft, writing, Muhammad Amir Abass and Javed Ali studied computational work, Amin Abid supervision, Manahal Abbas and Sadia Shabbir studied Data validation and Rakia Ali Editing , Reviewing. All authors reviewed the manuscript outline.

Funding

No Funding

Data Availability

No datasets were created or analyzed in the course of this study.

Competing Interests

There are no conflicts of interest exist among authors of this research paper.

Consent to participate

Not applicable.

Consent for publications

The article does not contain any material that is offensive, defamatory, or that would, in any way, violate the terms and conditions outlined in the agreement if published.

REFERENCES

1. Hulvat, M.C., *Cancer incidence and trends*. Surgical Clinics, 2020. **100**(3): p. 469-481.
2. Sung, H., et al., *Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA: a cancer journal for clinicians, 2021. **71**(3): p. 209-249.
3. Abdelatty, M.M., et al., *Synthesis, Antimicrobial Studies, and Molecular Docking Simulation of Novel Pyran, Pyrazole, and Pyranopyrazole Derivatives*. Journal of Chemistry, 2023. **2023**(1): p. 6623445.
4. Nishanth Rao, R., et al., *Green synthesis of biologically active heterocycles of medicinal importance: A review*. Environmental Chemistry Letters, 2021. **19**: p. 3315-3358.
5. Kumar, N. and N. Goel, *Heterocyclic Compounds: Importance in Anticancer Drug Discovery*. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2022. **22**(19): p. 3196-3207.
6. Rotella, D.P., *Heterocycles in drug discovery: Properties and preparation*, in *Advances in Heterocyclic Chemistry*. 2021, Elsevier. p. 149-183.
7. Lang, D.K., et al., *Nitrogen-containing heterocycles as anticancer agents: An overview*. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2020. **20**(18): p. 2150-2168.

8. Zhang, Y., et al., *Recent advances in the development of pyrazole derivatives as anticancer agents*. International Journal of Molecular Sciences, 2023. **24**(16): p. 12724.
9. Panchal, N.B., et al., *Acridine a versatile heterocyclic moiety as anticancer agent*. 2020.
10. Marín-Ocampo, L., et al., *Anti-inflammatory activity of triazine derivatives: A systematic review*. European Journal of Medicinal Chemistry, 2019. **162**: p. 435-447.
11. Kabir, E. and M. Uzzaman, *A review on biological and medicinal impact of heterocyclic compounds*. Results in Chemistry, 2022. **4**: p. 100606.
12. Li, M. and B.-X. Zhao, *Progress of the synthesis of condensed pyrazole derivatives (from 2010 to mid-2013)*. European Journal of Medicinal Chemistry, 2014. **85**: p. 311-340.
13. Mamaghani, M. and R. Hossein Nia, *A review on the recent multicomponent synthesis of pyranopyrazoles*. Polycyclic Aromatic Compounds, 2021. **41**(2): p. 223-291.
14. Baranwal, J., et al., *A review on the synthesis and pharmacological activity of heterocyclic compounds*. Current Physical Chemistry, 2023. **13**(1): p. 2-19.
15. Reddy, G.M., et al., *Novel pyranopyrazole derivatives comprising a benzoxazole core as antimicrobial inhibitors: Design, synthesis, microbial resistance and machine aided results*. Bioorganic chemistry, 2020. **100**: p. 103908.
16. Nassar, I.F.F., et al., *Design, Synthesis and Biological Evaluation of Novel Pyrano [2, 3-*c*] pyrazoles And Their Sugar Derivatives as Antimicrobial, Antioxidant and Anticancer Agents*. Egyptian Journal of Chemistry, 2022. **65**(132): p. 1489-1505.
17. Priya, D., et al., *Structural Insights into Pyrazoles as Agents against Anti-inflammatory and Related Disorders*. ChemistrySelect, 2022. **7**(5): p. e202104429.
18. Chaudhry, F., et al., *Exploring facile synthesis and cholinesterase inhibiting potential of heteroaryl substituted imidazole derivatives for the treatment of Alzheimer's disease*. Arabian Journal of Chemistry, 2023. **16**(1): p. 104384.
19. Kumar, A., et al., *Design, synthesis, computational and biological evaluation of some new hydrazino derivatives of DHA and pyranopyrazoles*. European journal of medicinal chemistry, 2012. **50**: p. 81-89.
20. Gorle, S., et al., *Synthesis and anticancer activity of novel pyrazolo [4', 3': 5, 6] pyrano [2, 3-*d*] pyrimidin-5 (2*H*)-one derivatives*. Chemical Data Collections, 2020. **28**: p. 100471.

21. Bakhotmah, D.A., et al., *Synthesis of some novel 2-{pyrano [2, 3-c] pyrazoles-4-ylidene} malononitrile fused with pyrazole, pyridine, pyrimidine, diazepine, chromone, pyrano [2, 3-c] pyrazole and pyrano [2, 3-d] pyrimidine systems as anticancer agents*. Polycyclic Aromatic Compounds, 2022. **42**(5): p. 2136-2150.
22. Asif, M., et al., *Lewis base-catalyzed synthesis of highly functionalized spirooxindole-pyranopyrazoles and their in vitro anticancer studies*. Medicinal Chemistry Research, 2023. **32**(5): p. 1001-1015.
23. Saleh, R.O., et al., *RETRACTED: Synthesis of Bioactive Yttrium-Metal–Organic Framework as Efficient Nanocatalyst in Synthesis of Novel Pyrazolopyranopyrimidine Derivatives and Evaluation of Anticancer Activity*. Frontiers in Chemistry, 2022. **10**: p. 928047.
24. Agrwal, A., R.K. Pathak, and V. Kasana, *Molecular docking and antibacterial studies of pyranopyrazole derivatives synthesized using [Pap-Glu@ Chi] biocatalyst through a greener approach*. Arabian Journal for Science and Engineering, 2022: p. 1-17.
25. Shamsuddin, M.A., et al., *Synthesis and Molecular Docking Studies of Pyrano [2, 3-c] Pyrazole-3-Carboxylates as Potential Inhibitors of Plasmodium Falciparum*. Malays. J. Chem, 2020. **22**(4): p. 52-61.
26. Mazzorana, M., E.J. Shotton, and D.R. Hall, *A comprehensive approach to X-ray crystallography for drug discovery at a synchrotron facility—The example of Diamond Light Source*. Drug Discovery Today: Technologies, 2020. **37**: p. 83-92.
27. Singh, S., Q.B. Baker, and D.B. Singh, *Molecular docking and molecular dynamics simulation*, in *Bioinformatics*. 2022, Elsevier. p. 291-304.
28. Agnihotry, S., et al., *Molecular docking and structure-based drug design*. Computer-aided drug design, 2020: p. 115-131.
29. Raval, K. and T. Ganatra, *Basics, types and applications of molecular docking: A review*. IP International Journal of Comprehensive and Advanced Pharmacology, 2022. **7**(1): p. 12-16.
30. Stanzione, F., I. Giangreco, and J.C. Cole, *Use of molecular docking computational tools in drug discovery*. Progress in medicinal chemistry, 2021. **60**: p. 273-343.
31. Guerroudj, A.R., et al., *Synthesis, crystal structure, vibrational spectral investigation, intermolecular interactions, chemical reactivity, NLO properties and molecular docking analysis on (E)-N-(4-nitrobenzylidene)-3-chlorobenzenamine: A combined experimental and theoretical study*. Journal of Molecular Structure, 2021. **1240**: p. 130589.

32. Dege, N., et al., *Theoretical and experimental approaches of new Schiff bases: efficient synthesis, X-ray structures, DFT, molecular modeling and ADMET studies*. Journal of the Iranian Chemical Society, 2021. **18**: p. 2345-2368.
33. Şahin, S. and N. Dege, *Synthesis, characterization, X-ray, HOMO-LUMO, MEP, FT-IR, NLO, Hirshfeld surface, ADMET, boiled-egg model properties and molecular docking studies with human cyclophilin D (CypD) of a Schiff base compound: (E)-1-(5-nitro-2-(piperidin-1-yl) phenyl)-N-(3-nitrophenyl) methanimine*. Polyhedron, 2021. **205**: p. 115320.
34. Sayer, I., et al., *Crystal structure, DFT studies and thermal characterization of new luminescent stannate (IV) based inorganic-organic hybrid compound*. Journal of Molecular Structure, 2021. **1224**: p. 129266.
35. Inac, H., et al., *Synthesis, spectroscopic characterizations, single crystal XRD, supramolecular assembly inspection via hirshfeld surface analysis, and DFT study of a hydroxy functionalized schiff base Cu (II) complex*. Journal of Molecular Structure, 2024. **1295**: p. 136751.
36. Avci, D., et al., *A novel series of mixed-ligand M (II) complexes containing 2, 2'-bipyridyl as potent alpha-glucosidase inhibitor: synthesis, crystal structure, DFT calculations, and molecular docking (vol 24, pg 747, 2019)*. Journal of Biological Inorganic Chemistry, 2021.
37. Saidj, M., et al., *Molecular structure, experimental and theoretical vibrational spectroscopy, (HOMO-LUMO, NBO) investigation, (RDG, AIM) analysis, (MEP, NLO) study and molecular docking of ethyl-2-{[4-Ethyl-5-(Quinolin-8-yloxyMethyl)-4H-1, 2, 4-Triazol-3-yl] Sulfanyl} acetate*. Polycyclic Aromatic Compounds, 2023. **43**(3): p. 2152-2176.
38. Agu, P., et al., *Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management*. Scientific Reports, 2023. **13**(1): p. 13398.